Prevalence and costs of Parkinsonian syndromes associated with orthostatic hypotension

Therapie

Volumn 61, Issue 2, 2006, Pages 93-99

  Desboeuf, Karine ^a   Grau, Maryse ^b   Riche, Françoise ^c   Fradin, Marc ^c   Bez, Jacques ^c   Montastruc, Jean Louis ^a   Senard, Jean Michel ^a,d  

^a INSERM   (France)

^b Caisse Primaire d'Assurance Maladie de la Haute Garonne   (France)

^c Service de Protection Maternelle et Infantile   (France)

^d UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Cost analysis; Cost of illness; Orthostatic hypotension; Parkinsonian syndromes

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; CAFEDRINE PLUS THEODRENALINE; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIHYDROERGOTAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ETILEFRINE; FLUDROCORTISONE; GASTROINTESTINAL AGENT; HEPTAMINOL; HYPERTENSIVE AGENT; LEVODOPA; LISURIDE; MIDODRINE; ORCIPRENALINE; PIRIBEDIL; ROPINIROLE; SELEGILINE; YOHIMBINE;

ADULT; AGED; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH CARE COST; HOSPITAL CHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; TREATMENT OUTCOME; COST OF ILLNESS; ECONOMICS; FRANCE; MIDDLE AGED; PARKINSONISM;

ANTIPARKINSON AGENTS; COST OF ILLNESS; FRANCE; HUMANS; HYPOTENSION, ORTHOSTATIC; MIDDLE AGED; PARKINSONIAN DISORDERS; PRESCRIPTIONS, DRUG; PREVALENCE;

EID: 33747154556     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2006020     Document Type: Article

References (42)

1. Ensrud KE, Nevitt MC, Yunis C, et al. Postural hypotension and postural dizziness in elderly women. The study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. Arch Intern Med 1992; 152: 1058-64
2. Rutan GH, Hermanson B, Bild DE, et al. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension 1992; 19: 508-19
3. Raiha I, Luutonen S, Piha J, et al. Prevalence, predisposing factors, and prognostic importance of postural hypotension. Arch Intern Med 1995; 155: 930-5
4. Elmstahl S, Rosen I. Postural hypotension and EEG variables predict cognitive decline: results from a 5-year follow-up of healthy elderly women. Dement Geriatr Cogn Disord. 1997; 8: 180-7
5. Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke. The Atherosclerosis Risk in Communities (ARIC) study, 1987-1996. Stroke 2000; 31: 2307-13
6. Rose KM, Tyroler HA, Nardo CJ, et al. Orthostatic hypotension and the incidence of coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Hypertens 2000; 13: 571-8
7. Masaki KH, Schatz IJ, Burchfiel CM, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation 1998; 98: 2290-5
8. Wenning GK, Tison F, Ben Shlomo Y, et al. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997; 12: 133-47
9. Korczyn AD. Autonomic nervous system disturbances in Parkinson's disease. Adv Neurol 1990; 53: 463-8
10. Senard JM, Rai S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63: 584-9
11. Senard JM, Brefel-Courbon C, Rascol O, et al. Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging 2001; 18: 495-505
12. Verhaeverbeke I, Mets T. Drug-induced orthostatic hypotension in the elderly: avoiding its onset. Drug Safety 1997; 17: 105-18
13. LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999; 16: 59-69
14. Lajugie D, Bertin N, Chantelou ML, et al. on behalf of the Medipath group. Prevalence de la maladie de Parkinson et coût pour l'Assurance Maladie en 2000 en France métropolitaine. Rev Med Ass Maladie 2005; 36: 113-22
15. Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998; 14: 299-312
16. Dodel RC, Eggert KM, Singer MS, et al. Costs of drug treatment in Parkinson's disease. Mov Disord 1998; 13: 249-54
17. Chrischilles EA, Rubenstein LM, Voelker MD, et al. The health burdens of Parkinson's disease. Mov Disord 1998; 13: 406-13
18. Anonymous. Anatomical Therapeutic Chemical (ATC) classification index including defined daily doses (DDDs) for plain substances. WHO Collaborating Centre for Drug Statistic Methodology, Norwegian Institute of Public Health. The ATC/DDD system. Available on URL http://www.whocc.no
19. Tison F, Dartigues JF, Dubes L, et al. Prevalence of Parkinson's disease in the elderly: a population study in Gironde, France. Acta Neurol Scand 1994; 90: 111-5
20. de Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 10-5
21. de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54(Suppl 5): S21-3
22. Van de Vijver DAMC, Stricker BHC, Breteler MMB, et al. Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease. Pharmacy World & Science 2001; 23: 148-52.
23. Van de Vijver DAMC, Roos RAC, Jansen PAF, et al. Estimation of incidence and prevalence of Parkinson's disease in elderly using pharmacy records. Pharmacoepidemiol Drug Saf 2001; 10: 549-54
24. Govoni V, Granieri E, Tola MR, et al. Prevalence of anti-parkinson drugs' use in Ferrara, northern Italy, 1988. Acta Neurol Scand 1994; 89: 433-8
25. Mathias CJ, Kimber JR. Treatment of postural hypotension. J Neurol Neurosurg Psychiatry 1998; 65: 285-289
26. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999; 354: 1771-5
27. Tison F, Yekhlef F, Chrysostome V, et al. Prevalence of multiple system atrophy. Lancet 2000; 355: 495-6
28. Wennings GK, Scherfler C, Granata R, et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry 1999; 67: 620-3
29. Brefel-Courbon C, Thalamas C, Rascol O, et al. Lack of autonomic nervous dysfunction in progressive supranuclear palsy, a study of blood pressure variability. Clin Auton Res 2000; 10: 309-12
30. Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2003; 2: 669-76
31. Camerlingo M, Ferraro B, Cazzaniga GC, et al. Cardiovascular reflexes in Parkinson's diesase: long term effects of levodopa treatment on de novo patients. Acta Neurol Scand 1990; 81: 346-8
32. Parker SG, Raval P, Yeulet S, et al. Tolerance to peripheral, but not central, effects of ropinirole, a selective dopamine D2-like receptor agonist. Eur J Pharmacol 1994; 265: 17-26
33. Teychenne PF, Rosin AJ, Plotkin CN, et al. Cross tolerance between two dopaminergic ergot derivatives, bromocriptine and lergotrile. Br J Clin Pharmacol 1980; 9: 47-50
34. Montastruc JL, Llau ME, Senard JM, et al. A study of tolerance to apomorphine. Br J Pharmacol 1996; 117: 781-86
35. van Dijk JG, Haan J, Zwinderman K, et al. Autonomic nervous system dysfunction in Parkinson's disease: relationship with age, medication, duration and severity. J Neurol Neurosurg Psychiatry 1993; 56: 1090-5
36. Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double blind placebo-controlled study with midodrine. Am J Med 1993; 95: 38-48
37. Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. JAMA 1997; 277(13): 1046-51
38. Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2003; 2: 669-76
39. Senard JM, Rascol O, Durrieu G, et al. Effects of yohimbine on plasma catecholamine levels in orthostatic hypotension related to Parkinson's disease or multiple system atrophy. Clin Neuropharmacol 1993; 16: 70-6
40. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology 1996; 46: 1470 [Letter]
41. Fahn S, Elton RL, UPDRS program members. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB eds. Recent developments in Parkinson's disease, vol 2, Florham Park, NJ, USA. McMillan Healthcare Information: 1987, pp 153-163
42. Movement disorder Society Task Force on rating scales for Parkinson's disease. The unified Parkinson's disease rating scale (UPDRS): status and recommendations. Mov Disord 2003; 18: 738-50